BUFFALO, N.Y. and HONG KONG, Oct. 25, 2016 /PRNewswire/ -- Athenex Pharmaceutical Division and Beijing Sciecure Pharmaceutical Co., Ltd., a specialty pharmaceutical company, today announced a binding agreement to launch and market 5 pharmaceutical products, all injectable, in the North America territory. These products are therapeutically relevant to the Athenex proprietary pipeline of products under development. The products will be launched in the future by Athenex Pharmaceutical Division.
Sciecure, a mid-sized company with many of its resources located in China, was established in 2007 and is headquartered in Beijing, China. It currently employs over 400 employees with offices in China, the USA, Canada and the U.K. Sciecure has Research & Development, manufacturing facilities with oral solid dosage forms, small volume parenteral, lyophilized powder for injection, ampoules, large volume parenteral and Active Pharmaceutical Ingredient (API), as well as marketing networks throughout China. The company has already received FDA acceptances on certain of their oral product filings which Athenex has the first right of refusal to market in the future.
Mr. Jeffrey Yordon, President of Athenex Pharmaceutical Division, stated "We are excited to have this opportunity to partner with Sciecure Pharma. Their extensive pipeline and development capability will serve both companies well in the near future. The combination of Athenex's sales, marketing, regulatory and quality infrastructure, combined with Sciecure's product development expertise and manufacturing expertise, make for a formidable combination of skill sets. The Sciecure Pharma partnership is another example of the growing number of partnerships we are executing to supply high value products to our markets. We are pleased to be working with an organization of Sciecure Pharma's caliber. The emphasis on product selection with Sciecure Pharma, and other future partners in oncology, will complement our robust proprietary pipeline of oral oncolytics. Opportunities like this enable Athenex to add to our infrastructure of our own sales, marketing and distribution systems prior to the launch of our first proprietary oncology product."
Mr. Shaohui Lin, Board Director of Sciecure, stated "Sciecure is very pleased to be a partner of Athenex. We have an extensive pipeline of both injectable and oral products that we will be working with Athenex in the future in North America. These pipeline products will be augmented by the fact that Sciecure owns its own API facility and we are back-integrated in many of our future products. This has a profound impact on the quality and the cost of the finished product."
The specialty products being launched in the near term are expected to create a revenue and margin contribution to help subsidize the ongoing clinical trials and research and development projects for the Athenex proprietary pipeline. To further the synergies, Athenex will be working closely with its own API division, Polymed, to back-integrate into the Athenex Pharmaceutical Division's pipeline of products.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms including an Oncology Innovation Platform, a U.S. Commercial Segment and an Internal Supply Chain. Our Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites, human absorption biology and through the application of our proprietary research and selection processes in the lab. Our current clinical pipeline is derived from two different platforms technologies we call Orascovery and Src Kinase Inhibition. The Orascovery platform is based on our belief that the next generation of cancer treatments will be driven by orally based cytotoxics allowing clinicians to potentially increase the amount of drug exposure per treatment cycle and increase the number of treatment cycles tolerated by patients. The Src Kinase inhibition platform includes novel small molecules addressing unmet medical needs that work through multi-mechanisms of action including inhibition of Src activities and tubulin polymerization inhibition. Athenex's several hundred employees are dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. We have offices in Buffalo and Clarence New York, Cranford, New Jersey, Houston, Texas, Chicago, Illinois, Hong Kong, Taipei Taiwan, and multiple locations in Chongqing, China.
For more information about Athenex's portfolio of proprietary products and clinical studies, please visit www.athenex.com
About Sciecure Pharma
Beijing Sciecure Pharmaceutical Co., Ltd, a mid-sized pharmaceutical company, was established in 2007, headquartered in Beijing, China, with over 400 employees and offices in the U.S., U.K. and Canada.
Bejing Sciecure has a manufacturing capability for oral solid dosage forms, SVP, lyophilized powder for injection, ampoules, LVP and API. With over 76,000 m2 of the land area and 2000 sales representatives, Sciecure's products get marketed across the entire landscape of the mainland China. Beijing Sciecure with a USA based pharmaceutical company jointly established a research laboratory in New Jersey. It currently employees over thirty pharmaceutical scientists, quality and regulatory personnel, dedicated to the development of high-barrier generic drugs.
Over the recent years, Beijing Sciecure has established quality management system complying with international GMP standards, allowing its product manufacturing to be in compliance with China FDA, USFDA and EU GMP.
For more information:
Last updated on: 26/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.